Your browser doesn't support javascript.
loading
Targeted dual base editing with Campylobacter jejuni Cas9 by single AAV-mediated delivery.
Kweon, Jiyeon; Jang, An-Hee; Kwon, Eunji; Kim, Ungi; Shin, Ha Rim; See, Jieun; Jang, Gayoung; Lee, Chaeyeon; Koo, Taeyoung; Kim, Seokjoong; Kim, Yongsub.
Affiliation
  • Kweon J; Department of Biomedical Sciences, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • Jang AH; Department of Biomedical Sciences, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • Kwon E; Stem Cell Immunomodulation Research Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • Kim U; Department of Fundamental Pharmaceutical Sciences, Kyung Hee University, Seoul, 02447, Republic of Korea.
  • Shin HR; Department of Biomedical and Pharmaceutical Sciences, Kyung Hee University, Seoul, 02447, Republic of Korea.
  • See J; Toolgen, Inc., Seoul, 08501, Republic of Korea.
  • Jang G; Department of Biomedical Sciences, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • Lee C; Stem Cell Immunomodulation Research Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • Koo T; Department of Biomedical Sciences, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • Kim S; Stem Cell Immunomodulation Research Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • Kim Y; Department of Biomedical Sciences, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
Exp Mol Med ; 55(2): 377-384, 2023 Feb.
Article in En | MEDLINE | ID: mdl-36720917
ABSTRACT
Various CRISPR‒Cas9 orthologs are used in genome engineering. One of the smallest Cas9 orthologs is cjCas9 derived from Campylobacter jejuni, which is a highly specific genome editing tool. Here, we developed cjCas9-based base editors including a cytosine base editor (cjCBEmax) and an adenine base editor (cjABE8e) that can successfully induce endogenous base substitutions by up to 91.2% at the HPD gene in HEK293T cells. Analysis of the base editing efficiency of 13 endogenous target sites showed that the active windows of cjCBEmax and cjABE8e are wider than those of spCas9-based base editors and that their specificities are slightly lower than that of cjCas9. Importantly, engineered cjCas9 and gRNA scaffolds can improve the base editing efficiency of cjABE8e by up to 6.4-fold at the HIF1A gene in HEK293T cells. Due to its small size, cjABE8e can be packaged in a single adeno-associated virus vector with two tandem arrays of gRNAs, and the delivery of the resulting AAV could introduce base substitutions at endogenous ANGPT2 and HPD target sites. Overall, our findings have expanded the potential of the use of base editors for in vivo or ex vivo therapeutic approaches.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Campylobacter jejuni / Gene Editing Limits: Humans Language: En Journal: Exp Mol Med Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Campylobacter jejuni / Gene Editing Limits: Humans Language: En Journal: Exp Mol Med Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA Year: 2023 Document type: Article